A pharmaceutical company usually builds relevance around a medicine. Organon is taking a wider approach. Its call for a coordinated European women’s health strategy raises a more interesting marketing question: Can advocacy for an entire healthcare category become part of a broader brand strategy in women’s health?
Organon has highlighted gaps in contraception access, research funding, medical education, and health data. Rather than centering the conversation on one treatment, the company is arguing that the environment around women’s healthcare needs to change. For pharma marketers, that shift matters. A company that helps define an unmet need can potentially build relevance long before a specific product enters the conversation. However, category advocacy only strengthens a brand when the public-health purpose remains credible on its own.
Table of Contents
- Why category advocacy is becoming a brand strategy
- How Organon is building around women’s health
- Where advocacy creates marketing value
- The credibility risk pharma marketers must manage
- Conclusion
- FAQ
Category Advocacy Is Moving Beyond Corporate Reputation
Traditional pharmaceutical brand building usually begins with a defined treatment, indication, or patient population. Category advocacy reverses that sequence. First, the company helps establish why a broader healthcare problem deserves attention. Then, over time, its products, partnerships, research, and corporate identity exist within that larger story.
Organon’s approach offers a clear example. The company has publicly called attention to differences in contraceptive access across Europe, limited investment in women-specific research, and gaps in sex-specific medical evidence. These issues extend well beyond any single medicine or campaign.
Meanwhile, European policymakers are also paying greater attention to women’s health. That includes discussions around better data, healthcare access, research priorities, and the way differences between men and women are considered in medicine development and care.
That alignment creates an important opportunity for pharmaceutical brands operating in women’s health. A company can participate in conversations that may shape the future of a healthcare category without reducing every discussion to product promotion.
However, advocacy is different from advertising. Its value comes from helping move an issue forward, even when there is no immediate prescription attached. For marketers, that distinction is increasingly important because patients, healthcare professionals, and policymakers can quickly recognize when advocacy feels like a disguised sales message.
A credible approach therefore requires consistency. Companies need to demonstrate that they are willing to support research, education, access, and awareness even when those efforts do not produce an immediate commercial return.
Organon Is Building Around the Category, Not Just Products
Organon has positioned women’s health as a central part of its corporate identity. Its portfolio spans areas including contraception, fertility, menopause, osteoporosis, bacterial vaginosis, and other conditions that affect women uniquely or differently.
The company has also invested in initiatives that extend beyond conventional product communications. Its Her Plan is Her Power program, for example, connects contraception access with education, advocacy, innovation, and partnerships. Organon has stated that the initiative is intended to help prevent millions of unintended pregnancies by expanding access to family-planning information and services.
That creates something broader than a collection of brands. Instead, it creates a recognizable strategic territory in which the company can participate consistently.
For marketers, the distinction is important. A strong strategy in women’s health may increasingly depend on having a meaningful point of view about the category rather than simply promoting a message about a molecule.
This trend also fits a wider change in healthcare marketing. Patients increasingly expect transparency, culturally relevant communication, and meaningful engagement rather than carefully polished health messages that feel disconnected from their real experiences.
As a result, companies that consistently participate in the issues surrounding care may develop a more durable identity than companies that appear only when a product needs promotion. Category involvement can help establish relevance before a patient or healthcare professional is even considering a specific treatment.
That does not mean pharmaceutical companies should attempt to own every conversation. Instead, the strongest positioning may come from identifying a few areas where a company has genuine expertise, resources, and a credible reason to participate.
Advocacy Can Expand the Definition of Brand Relevance
Category advocacy can create several forms of strategic value. First, it gives pharmaceutical companies an opportunity to participate in conversations earlier in the patient journey. Awareness of contraception access, delayed diagnosis, research inequality, or gaps in medical data can begin years before a treatment decision occurs.
Second, advocacy can connect companies with policymakers, clinicians, patient organizations, researchers, and healthcare systems. These relationships matter because healthcare decisions increasingly involve more than an individual physician.
Third, category leadership can give individual products more context. Instead of asking audiences to care about a treatment in isolation, the company can place that treatment within a recognized healthcare gap.
However, this does not mean every unmet need should become a marketing opportunity. That boundary is especially important for companies building brands in women’s health.
Reproductive health, menopause, fertility, maternal health, and other areas involve deeply personal experiences. Turning those experiences too quickly into commercial messaging can undermine the credibility that advocacy was supposed to create.
This is where a thoughtful women’s health brand strategy requires restraint. Companies need to understand when their role is to educate, when it is to support broader change, and when it is appropriate to talk about products.
In practice, the separation may not always be perfect. However, clear disclosures, credible evidence, and genuine collaboration with outside organizations can help make the company’s role easier to understand.
The Strongest Strategy May Be the One That Does Not Sell Immediately
For marketers, the temptation is obvious. If a company invests in advocacy, executives will eventually ask how that activity contributes to commercial value.
Yet measuring category advocacy only through near-term leads, prescriptions, or campaign engagement may miss the point. Credibility compounds slowly. A company that funds research, expands access, supports better data, educates clinicians, and works with independent organizations can gradually become associated with progress in a category.
Consequently, that reputation may influence future relationships with patients, healthcare professionals, policymakers, partners, and employees. The value is not always visible in a campaign dashboard, but it can shape how stakeholders interpret the company’s actions over time.
Still, brands need safeguards. Advocacy claims should be supported by evidence. Partnerships should include credible independent stakeholders. Educational materials should make the distinction between disease awareness and product promotion clear.
Moreover, marketers should avoid implying that one company or medicine can solve a systemic problem. Large healthcare gaps rarely have simple solutions, and exaggerating a company’s role can quickly weaken trust.
Instead, a thoughtful women’s health marketing strategy can show how commercial organizations may contribute to an environment where better care becomes possible. That contribution might include supporting research, improving access, funding education, or helping bring overlooked health issues into public discussion.
That is a harder story to tell than a traditional product campaign. Nevertheless, it may also be a more valuable one because it gives the company a role that extends beyond a single launch cycle.
Conclusion
Organon’s call for a European women’s health strategy illustrates how pharmaceutical branding is expanding beyond individual medicines. Category advocacy can help a company build relevance around research, access, education, data, and policy.
At the same time, it creates a demanding credibility test. The advocacy must deliver recognizable value even when no product is being discussed. Otherwise, stakeholders may see the effort as another form of promotion.
For pharma marketers, that may be the central lesson. The most sustainable approach to building a women’s health brand may not begin with asking how a company can own a category. It may begin with asking what the company can credibly contribute to improving it.
FAQ
What is a women’s health brand strategy?
A women’s health brand strategy defines how a healthcare company builds relevance, trust, and differentiation around the needs of women. It can include product marketing, education, research, advocacy, partnerships, access programs, and corporate positioning.
What is category advocacy in pharmaceutical marketing?
Category advocacy occurs when a company supports awareness, research, education, access, or policy change around a broader healthcare issue instead of focusing only on an individual product.
Can advocacy strengthen a pharmaceutical brand?
Yes, although the connection is usually indirect. Consistent, evidence-based advocacy can strengthen credibility, stakeholder relationships, and long-term category relevance. However, overly promotional messaging can weaken those benefits.
Why is women’s health attracting more pharmaceutical marketing attention?
Women’s health has historically faced gaps in research, data, diagnosis, and access. At the same time, conversations around menopause, reproductive health, fertility, contraception, and other conditions have become more visible, creating demand for better information and solutions.
How should pharma companies avoid making advocacy feel promotional?
Companies should separate education from product promotion, use credible evidence, involve independent partners, disclose commercial interests clearly, and demonstrate measurable contributions to the healthcare issue itself.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
